SGMT – sagimet biosciences inc. (US:NASDAQ)
Stock Stats
News
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences (SGMT) is now covered by Rodman & Renshaw. They set a "buy" rating and a $28.00 price target on the stock.
Sagimet Biosciences (SGMT) was upgraded by Wall Street Zen from "sell
Sagimet Biosciences (SGMT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $29.00 price target on the stock.
Form ARS Sagimet Biosciences Inc. For: Dec 31
Form DEF 14A Sagimet Biosciences Inc. For: Jun 12
Form 8-K Sagimet Biosciences Inc. For: Apr 20
Form S-8 Sagimet Biosciences Inc.
Form S-8 Sagimet Biosciences Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.